Neuphoria Therapeutics (NASDAQ:NEUP) Posts Earnings Results, Beats Estimates By $0.47 EPS

Neuphoria Therapeutics (NASDAQ:NEUP) released its quarterly earnings results on Friday. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.47, FiscalAI reports.

Neuphoria Therapeutics Stock Performance

NEUP traded down $0.36 during midday trading on Friday, reaching $4.73. The company had a trading volume of 79,662 shares, compared to its average volume of 45,000. The stock has a market cap of $25.49 million, a PE ratio of -1.07 and a beta of 0.72. Neuphoria Therapeutics has a 12-month low of $3.64 and a 12-month high of $21.40. The business has a 50-day moving average price of $4.72 and a two-hundred day moving average price of $4.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Diadema Partners LP boosted its stake in Neuphoria Therapeutics by 133.1% in the fourth quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock valued at $194,000 after acquiring an additional 28,548 shares during the last quarter. Ikarian Capital LLC purchased a new position in Neuphoria Therapeutics in the fourth quarter valued at about $184,000. ADAR1 Capital Management LLC purchased a new position in Neuphoria Therapeutics in the fourth quarter valued at about $116,000. Millennium Management LLC purchased a new position in Neuphoria Therapeutics in the third quarter valued at about $216,000. Finally, Geode Capital Management LLC boosted its stake in Neuphoria Therapeutics by 33.3% in the fourth quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock valued at $67,000 after acquiring an additional 4,325 shares during the last quarter. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. HC Wainwright cut shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, January 22nd. Finally, Zacks Research upgraded shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Neuphoria Therapeutics presently has a consensus rating of “Hold” and an average target price of $21.00.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.